Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Baxter
Colorcon
Moodys
Boehringer Ingelheim

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,511,046

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 9,511,046 protect, and when does it expire?

Patent 9,511,046 protects ABRAXANE and is included in one NDA.

This patent has eighteen patent family members in thirteen countries.

Summary for Patent: 9,511,046
Title:Methods of treating pancreatic cancer
Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.
Inventor(s): Desai; Neil P. (Los Angeles, CA), Renschler; Markus (San Francisco, CA)
Assignee: ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA)
Application Number:13/794,480
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,511,046
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Recent additions to Drugs Protected by US Patent 9,511,046

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION 021660 Jan 7, 2005 RX Yes   Start Trial   Start Trial U-1434 TREATMENT OF PANCREATIC CANCER
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 9,511,046

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes   Start Trial   Start Trial TREATMENT OF PANCREATIC CANCER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Colorcon
Baxter
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.